Top

Published in:

14-08-2023 | Parkinson's Disease | Original article

Quantitative susceptibility mapping from basal ganglia and related structures: correlation with disease severity in progressive supranuclear palsy

Authors: Syam Krishnan, Sneha Susan George, Vineeth Radhakrishnan, Sheelakumari Raghavan, Bejoy Thomas, Jissa Vinoda Thulaseedharan, Divya Kalikavil Puthenveedu

Published in: Acta Neurologica Belgica | Issue 1/2024

Abstract

Objective

We examined whether mean magnetic susceptibility values from deep gray matter structures in patients with progressive supranuclear palsy (PSP) differed from those in patients with Parkinson’s disease (PD) and healthy volunteers, and correlated with the PSP rating scale.

Methods

Head of caudate nucleus, putamen, globus pallidus, substantia nigra and red nucleus were the regions of interest. Mean susceptibility values from these regions in PSP patients were estimated using quantitative susceptibility mapping. Correlations with clinical severity of disease as measured by the PSP rating scale were examined. The mean susceptibility values were also compared with those from healthy volunteers and age- and disease duration-matched patients with PD.

Results

Data from 26 healthy volunteers, 26 patients with PD and 27 patients with PSP, were analysed. Patients with PSP had higher mean susceptibility values from all regions of interest when compared to both the other groups. The PSP rating scale scores correlated strongly with mean susceptibility values from the red nucleus and moderately with those from the putamen and substantia nigra. The scores did not correlate with mean susceptibility values from the caudate nucleus or globus pallidus. In patients with PD, the motor deficits correlated moderately with mean susceptibility values from substantia nigra.

Conclusions

In patients with PSP, mean susceptibility values indicating the severity of mineralization of basal ganglia and related structures correlate with disease severity, the correlation of red nucleus being the strongest. Further studies are warranted to explore whether mean susceptibility values could serve as biomarkers for PSP.

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1–9. https://doi.org/10.1212/WNL.47.1.1CrossRefPubMed

Golbe LI (2014) Progressive supranuclear palsy. Semin Neurol 34(2):151–159. https://doi.org/10.1055/s-0034-1381736CrossRefPubMed

Armstrong MJ (2018) Progressive supranuclear palsy: an update. Curr Neurol Neurosci Rep 18(3):12. https://doi.org/10.1007/s11910-018-0819-5CrossRefPubMed

Giagkou N, Höglinger GU, Stamelou M (2019) Progressive supranuclear palsy. Int Rev Neurobiol 149:49–86. https://doi.org/10.1016/bs.irn.2019.10.013CrossRefPubMed

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE et al (2017) Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 32(6):853–864. https://doi.org/10.1002/mds.26987CrossRefPubMedPubMedCentral

Parmera JB, Oliveira MCB, Rodrigues RD, Coutinho AM (2022) Progressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkers. Arq Neuropsiquiatr 80(5 Suppl 1):126–136. https://doi.org/10.1590/0004-282x-anp-2022-s134CrossRefPubMedPubMedCentral

Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16(7):552–563. https://doi.org/10.1016/s1474-4422(17)30157-6CrossRefPubMedPubMedCentral

Jabbari E, Zetterberg H, Morris HR (2017) Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatr 88:883–888. https://doi.org/10.1136/jnnp-2017-315857CrossRef

Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13(10):1045–1060. https://doi.org/10.1016/s1474-4422(14)70117-6CrossRefPubMedPubMedCentral

10.

Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE et al (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(4):1953–1975. https://doi.org/10.1093/brain/114.4.1953CrossRefPubMed

11.

Sehgal V, Delproposto Z, Haacke EM, Tong KA, Wycliffe N, Kido DK et al (2005) Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 22(4):439–450. https://doi.org/10.1002/jmri.20404CrossRefPubMed

12.

Gupta D, Saini J, Kesavadas C, Sarma PS, Kishore A (2010) Utility of susceptibility-weighted MRI in differentiating Parkinson’s disease and atypical parkinsonism. Neuroradiology 52(12):1087–1094. https://doi.org/10.1007/s00234-010-0677-6CrossRefPubMed

13.

Haacke EM, Liu S, Buch S, Zheng W, Wu D, Ye Y (2015) Quantitative susceptibility mapping: current status and future directions. Magn Reson Imaging 33(1):1–25. https://doi.org/10.1016/j.mri.2014.09.004CrossRefPubMed

14.

Eskreis-Winkler S, Zhang Y, Zhang J, Liu Z, Dimov A, Gupta A et al (2017) The clinical utility of QSM: disease diagnosis, medical management, and surgical planning. NMR Biomed. https://doi.org/10.1002/nbm.3668CrossRefPubMed

15.

Sheelakumari R, Madhusoodanan M, Radhakrishnan A, Ranjith G, Thomas B (2016) A potential biomarker in amyotrophic lateral sclerosis: can assessment of brain iron deposition with swi and corticospinal tract degeneration with DTI Help? Am J Neuroradiol 37(2):252–258. https://doi.org/10.3174/ajnr.a4524CrossRefPubMedPubMedCentral

16.

Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E et al (2012) Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post-mortem validation study. Neuroimage 62(3):1593–1599. https://doi.org/10.1016/j.neuroimage.2012.05.049CrossRefPubMed

17.

Sjöström H, Granberg T, Westman E, Svenningsson P (2017) Quantitative susceptibility mapping differentiates between Parkinsonian disorders. Parkinsonism Relat Disord 44:51–57. https://doi.org/10.1016/j.parkreldis.2017.08.029CrossRefPubMed

18.

Mazzucchi S, Frosini D, Costagli M, Del Prete E, Donatelli G, Cecchi P et al (2019) Quantitative susceptibility mapping in atypical Parkinsonisms. Neuroimage Clin 24:101999. https://doi.org/10.1016/j.nicl.2019.101999CrossRefPubMedPubMedCentral

19.

Harder SL, Hopp KM, Ward H, Neglio H, Gitlin J, Kido D (2008) Mineralization of the deep gray matter with age: a retrospective review with susceptibility-weighted MR imaging. Am J Neuroradiol 29(1):176–183. https://doi.org/10.3174/ajnr.a0770CrossRefPubMedPubMedCentral

20.

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr 55(3):181–184. https://doi.org/10.1136/jnnp.55.3.181CrossRef

21.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424CrossRefPubMed

22.

Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B (2005) Clinical characteristics in early Parkinson’s disease in a central California population-based study. Mov Disord 20(9):1133–1142. https://doi.org/10.1002/mds.20513CrossRefPubMedPubMedCentral

23.

Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130(6):1552–1565. https://doi.org/10.1093/brain/awm032CrossRefPubMed

24.

Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarriés J, Bermejo F (1994) Unified Parkinson’s disease rating scale characteristics and structure. The cooperative multicentric group. Mov Disord 9(1):76–83. https://doi.org/10.1002/mds.870090112CrossRefPubMed

25.

Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T et al (1992) Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 7(1):2–13. https://doi.org/10.1002/mds.870070103CrossRefPubMed

26.

Krishnan S, Prasad S, Pisharady KK, Sarma G, Sarma SP, Kishore A (2016) The decade after subthalamic stimulation in advanced Parkinson’s disease: a balancing act. Neurol India 64(1):81–89. https://doi.org/10.4103/0028-3886.173663CrossRefPubMed

27.

Vinayagamani S, Sheelakumari R, Sabarish S, Senthilvelan S, Ros R, Thomas B et al (2020) Quantitative susceptibility mapping: technical considerations and clinical applications in neuroimaging. J Magn Reson Imaging 53(1):23–37. https://doi.org/10.1002/jmri.27058CrossRefPubMed

28.

Smith SM (2002) Fast robust automated brain extraction. Hum Brain Mapp 17(3):143–155. https://doi.org/10.1002/hbm.10062CrossRefPubMedPubMedCentral

29.

Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC et al (2006) User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 31(3):1116–1128. https://doi.org/10.1016/j.neuroimage.2006.01.015CrossRefPubMed

30.

Langkammer C, Pirpamer L, Seiler S, Deistung A, Schweser F, Franthal S et al (2016) Quantitative susceptibility mapping in Parkinson’s disease. PloS One 11(9):e0162460. https://doi.org/10.1371/journal.pone.0162460CrossRefPubMedPubMedCentral

31.

Ito K, Ohtsuka C, Yoshioka K, Kameda H, Yokosawa S, Sato R et al (2017) Differential diagnosis of parkinsonism by a combined use of diffusion kurtosis imaging and quantitative susceptibility mapping. Neuroradiology 59(8):759–769. https://doi.org/10.1007/s00234-017-1870-7CrossRefPubMed

32.

Fedeli MP, Contarino VE, Siggillino S, Samoylova N, Calloni S, Melazzini L et al (2020) Iron deposition in Parkinsonisms: a quantitative susceptibility mapping study in the deep grey matter. Eur J Radiol 133:109394. https://doi.org/10.1016/j.ejrad.2020.109394CrossRefPubMed

33.

Barsottini OGP, Felício AC, de Aquino CCH, Pedroso JL (2010) Progressive supranuclear palsy: new concepts. Arq Neuropsiquiatr 68(6):938–946. https://doi.org/10.1590/s0004-282x2010000600020CrossRefPubMed

34.

Azuma M, Hirai T, Nakaura T, Kitajima M, Yamashita S, Hashimoto M et al (2019) Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson’s disease. J Neurol Sci 406:116443. https://doi.org/10.1016/j.jns.2019.116443CrossRefPubMed

35.

Chen J, Cai T, Li Y, Chi J, Rong S, He C et al (2020) Different iron deposition patterns in Parkinson’s disease subtypes: a quantitative susceptibility mapping study. Quant Imaging Med Surg 10(11):2168–2176. https://doi.org/10.21037/qims-20-285CrossRefPubMedPubMedCentral

36.

Guan X, Xuan M, Gu Q, Xu X, Huang P, Wang N et al (2017) Influence of regional iron on the motor impairments of Parkinson’s disease: a quantitative susceptibility mapping study. J Magn Reson Imaging 45(5):1335–1342. https://doi.org/10.1002/jmri.25434CrossRefPubMed

37.

Xuan M, Guan X, Gu Q, Shen Z, Yu X, Qiu T et al (2017) Different iron deposition patterns in early-and middle-late-onset Parkinson’s disease. Parkinsonism Relat Disord 44:23–27. https://doi.org/10.1016/j.parkreldis.2017.08.013CrossRefPubMed

38.

Li KR, Avecillas-Chasin J, Nguyen TD, Gillen KM, Dimov A, Chang E et al (2022) Quantitative evaluation of brain iron accumulation in different stages of Parkinson’s disease. J Neuroimaging 32(2):363–371. https://doi.org/10.1111/jon.12957CrossRefPubMed

39.

Hallgren B, Sourander P (1958) The effect of age on the non-haemin iron in the human brain. J Neurochem 3(1):41–51. https://doi.org/10.1111/j.1471-4159.1958.tb12607.xCrossRefPubMed

40.

Ramos P, Santos A, Pinto NR, Mendes R, Magalhães T, Almeida A (2014) Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes. J Trace Elem Med Biol 28(1):13–17. https://doi.org/10.1016/j.jtemb.2013.08.001CrossRefPubMed

41.

Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan EV, Adalsteinsson E (2012) MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 59(3):2625–2635. https://doi.org/10.1016/j.neuroimage.2011.08.077CrossRefPubMed

42.

Treit S, Naji N, Seres P, Rickard J, Stolz E, Wilman AH et al (2021) R2* and quantitative susceptibility mapping in deep gray matter of 498 healthy controls from 5 to 90 years. Hum Brain Mapp 42(14):4597–4610. https://doi.org/10.1002/hbm.25569CrossRefPubMedPubMedCentral

43.

He N, Ling H, Ding B, Huang J, Zhang Y, Zhang Z et al (2015) Region-specific disturbed iron distribution in early idiopathic Parkinson’s disease measured by quantitative susceptibility mapping. Hum Brain Mapp 36(11):4407–4420. https://doi.org/10.1002/hbm.22928CrossRefPubMedPubMedCentral

44.

An H, Zeng X, Niu T, Li G, Yang J, Zheng L et al (2018) Quantifying iron deposition within the substantia nigra of Parkinson’s disease by quantitative susceptibility mapping. J Neurol Sci 386:46–52. https://doi.org/10.1016/j.jns.2018.01.008CrossRefPubMed

45.

Du G, Wang E, Sica C, Chen H, De Jesus S, Lewis MM et al (2022) Dynamics of nigral iron accumulation in Parkinson’s disease: from diagnosis to late stage. Mov Disord 37(8):1654–1662. https://doi.org/10.1002/mds.29062CrossRefPubMedPubMedCentral

46.

Hall DA, Forjaz MJ, Golbe LI, Litvan I, Payan CAM, Goetz CG et al (2015) Scales to assess clinical features of progressive supranuclear Palsy: MDS task force report. Mov Disord Clin Pract 2(2):127–134. https://doi.org/10.1002/mdc3.12130CrossRefPubMedPubMedCentral

47.

Hattori M, Hashizume Y, Yoshida M, Iwasaki Y, Hishikawa N, Ueda R et al (2003) Distribution of astrocytic plaques in the corticobasal degeneration brain and comparison with tuft-shaped astrocytes in the progressive supranuclear palsy brain. Acta Neuropathol (Berl) 106(2):143–149. https://doi.org/10.1007/s00401-003-0711-4CrossRefPubMed

48.

Cosottini M, Frosini D, Pesaresi I, Donatelli G, Cecchi P, Costagli M et al (2015) Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease. Am J Neuroradiol 36(3):461–466. https://doi.org/10.3174/ajnr.a4158CrossRefPubMedPubMedCentral

49.

Ghourchian S, Mousavi A, Zamani B, Shahidi G, Rohani M (2019) Midbrain area for differentiating Parkinson’s disease from progressive supranuclear palsy. Clin Neurol Neurosurg 183:105383. https://doi.org/10.1016/j.clineuro.2019.105383CrossRefPubMed

Title: Quantitative susceptibility mapping from basal ganglia and related structures: correlation with disease severity in progressive supranuclear palsy
Authors: Syam Krishnan
Sneha Susan George
Vineeth Radhakrishnan
Sheelakumari Raghavan
Bejoy Thomas
Jissa Vinoda Thulaseedharan
Divya Kalikavil Puthenveedu
Publication date: 14-08-2023
Publisher: Springer International Publishing
Keywords: Parkinson's Disease
Progressive Supranuclear Palsy
Published in: Acta Neurologica Belgica / Issue 1/2024
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-023-02352-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quantitative susceptibility mapping from basal ganglia and related structures: correlation with disease severity in progressive supranuclear palsy

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Central retinal artery occlusion caused by radiation-induced carotid stenosis

Natural history of extracranial carotid vasospasm: a case followed up after 6 years

Hereditary polyneuropathy with conduction block associated with SORD mutation in three siblings

A case of neuroborreliosis with striking abnormalities on brain MRI

Rapidly progressive dementia with focal symptoms: when to suspect Creutzfeldt–Jakob disease?

Paraneoplastic Stiff-Person syndrome with adenocarcinoma of the bladder and anti-glycine receptor antibodies